KPC Pharmaceuticals Inc (KPC) is a pharmaceutical company. It manufactures and sells botanical drugs and other pharmaceutical products. The company offers products that comprise panax notoginseng, artemether, gastrodine, Chinese medicines and special botanical drugs. It provides products under tablet, capsule and injection. KPC’s drugs are used for the treatment of central nervous system disorders, cardiovascular, cardio-cerebral-vascular, chronic disease, disorders and malaria. It also offers research and development, marketing, production, commercial wholesale and international marketing services. The company serves its products under the brands Tianxuanqing, Luotai, Artemedine, Arco and Artem. KPC is headquartered in Kunming, Yunnan, China.
Headquarters
China
Address
No.166 Keyi Road, State New and High-Tech Development Zone, Kunming, Yunnan, 650106
Website
www.kpc.com.cn
Telephone
86 871 68319868
No of Employees
5,322
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600422 (SHA)
Revenue (2022)
$1.2B
0.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-24.5%
(2022 vs 2021)
Market Cap*
$2.2B
Net Profit Margin (2022)
XYZ
-24.7%
(2022 vs 2021)
* As of and is in US$
KPC Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Artemether | Research and Development | Artem |
| Botanical Drugs | International Marketing | Arco |
| Gastrodine | Luotai | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
Competitor Comparison
| Key Parameters | KPC Pharmaceuticals Inc | Jointown Pharmaceutical Group Co Ltd | Shenzhen Neptunus Bioengineering Co Ltd | Harbin Pharmaceutical Group Co Ltd | Jiangsu Nhwa Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Kunming | Wuhan | Shenzhen | Haerbin | Xuzhou |
| State/Province | Yunnan | Hubei | Guangdong | Heilongjiang | Jiangsu |
| No. of Employees | 5,322 | 30,141 | 9,874 | 10,064 | 4,955 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Qiu Huawei | Chairman | Executive Board | 2023 | 56 |
| Yan Wei | Vice Chairman; President | Executive Board | 2023 | 52 |
| Li Shuangyou | Vice Chairman | Executive Board | - | 55 |
| Zhang Mengxun | Secretary | Senior Management | 2020 | 45 |
| Sun Zhiqiang | Director - Financial | Senior Management | 2023 | 43 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward